Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CYTH Nasdaq 2833 https://www.cyclotherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclo Therapeutics Inc

Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - May 12th, 2022 8:05 pm
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event - May 9th, 2022 12:05 pm
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event - Mar 29th, 2022 12:35 pm
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline - Mar 24th, 2022 12:05 pm
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest - Mar 23rd, 2022 12:25 pm
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results - Mar 14th, 2022 12:05 pm
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference - Mar 10th, 2022 1:05 pm
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022 - Feb 8th, 2022 1:05 pm
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C - Feb 3rd, 2022 1:05 pm
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference - Jan 20th, 2022 1:05 pm
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th - Jan 12th, 2022 3:35 pm
Here's Why Cyclo Therapeutics (NASDAQ:CYTH) Must Use Its Cash Wisely - Dec 16th, 2021 11:16 am
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease - Dec 9th, 2021 1:05 pm
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease - Dec 6th, 2021 1:05 pm
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock - Nov 17th, 2021 1:28 am
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock - Nov 16th, 2021 9:27 pm
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease - Nov 16th, 2021 1:05 pm
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Nov 15th, 2021 9:20 pm
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event - Nov 10th, 2021 1:05 pm